HN-1 peptide

a tumor-specific peptide that may prove suitable for drug delivery

Also Known As:

TSPLNIHNGQKL; threonyl-seryl-prolyl-leucyl-asparagyl-isoleucyl-histidyl-asparagyl-glycyl-glutaminyl-lysyl-leucine

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - HN-1 peptide: 4

Experts

1.	Castro, Miguel: 1 article (05/2022)
2.	Hong, Frank-Un: 1 article (05/2022)
3.	Linse, Klaus: 1 article (05/2022)
4.	Du, Jie: 1 article (01/2021)
5.	Duan, Ailin: 1 article (01/2021)
6.	Gao, Ruifang: 1 article (01/2021)
7.	Li, Bing: 1 article (01/2021)
8.	Li, Ran: 1 article (01/2021)
9.	Liu, Junyu: 1 article (01/2021)
10.	Wang, Xiangyu: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 05/24/2022 - "Further studies are warranted to assess HN-1 peptide's interaction with DDR1 and the therapeutic potential of treating metastatic cancer. " 01/01/2011 - "Targeting of HN-1 peptide was compared in normal epithelial cells (BEAS-2B) and in HNSCC tumor cells (SCC-25 and Detroit 562). " 05/24/2022 - "The discovery of DDR1 as HN-1 peptide's putative receptor represents a significant advance as it enables identification of metastatic cancers or clinical application of previously developed therapeutics to block metastasis."
2.	Squamous Cell Carcinoma of Head and Neck 01/01/2011 - "Targeting of HN-1 peptide was compared in normal epithelial cells (BEAS-2B) and in HNSCC tumor cells (SCC-25 and Detroit 562). " 06/15/2017 - "PEGylated doxorubicin nanoparticles mediated by HN-1 peptide for targeted treatment of oral squamous cell carcinoma." 01/01/2021 - "Moreover, we designed an effective nanoparticle system for the doxorubicin (DOX) delivery targeting the oral squamous cell carcinoma (OSCC) by mediating the HN-1 (TSPLNIHNGQKL) through hydrogen and π-π bonds. "
3.	Neoplasm Metastasis (Metastasis) 05/24/2022 - "The discovery of DDR1 as HN-1 peptide's putative receptor represents a significant advance as it enables identification of metastatic cancers or clinical application of previously developed therapeutics to block metastasis." 05/24/2022 - "The clues that led to DDR1 involved in metastasis as the putative receptor mediating HN-1 endocytosis are the following: (1) HN-1 is internalized in phosphate-buffered saline and its uptake is competitively inhibited; (2) HN-1 (TSPLNIHNGQKL) exhibits similarity with a stretch of amino acids in alpha5 beta3 integrin (KLLITIHDRKEF). "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Integrin beta3 (GPIIIa)
3.	Phosphates (Orthophosphate)
4.	Hydrogen
5.	Amino Acids

Related Therapies and Procedures

1.	Therapeutics